menu search

PIRS / Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read More
Posted: Sep 25 2023, 13:32
Author Name: Zacks Investment Research
Views: 111060

PIRS News  

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why

By Zacks Investment Research
September 25, 2023

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why

Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. T more_horizontal

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know

By Zacks Investment Research
August 23, 2023

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know

Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 more_horizontal

Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises

By Zacks Investment Research
July 19, 2023

Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises

Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep. more_horizontal

Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate

By Zacks Investment Research
June 23, 2023

Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate

Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinica more_horizontal

Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites

By Seeking Alpha
May 17, 2023

Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites

Expanding Elarekibep (AZD1402) trial finally has active/completed sites. Major investment risk exists because of the Company's cash burn rate. more_horizontal

Best Penny Stocks To Buy Now? 7 Under $1 To Watch

By PennyStocks
May 12, 2023

Best Penny Stocks To Buy Now? 7 Under $1 To Watch

Penny stocks under $1 to watch before next week. The post Best Penny Stocks To Buy Now? more_horizontal

Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
May 10, 2023

Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates

Pieris Pharmaceuticals (PIRS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares more_horizontal

Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 29, 2023

Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call Transcript

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q4 2022 Results Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Thomas Bures - Sen more_horizontal


Search within

Pages Search Results: